Glioma - Pipeline Insight, 2025

The “Glioma - Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Glioma: Understanding

Glioma: Overview

Glioma is a type of tumor that occurs in the glial cells of the brain or spine, which are supportive cells in the nervous system. These tumors are categorized based on the specific type of glial cell they originate from, such as astrocytes, oligodendrocytes, or ependymal cells. Gliomas can vary significantly in their aggressiveness, ranging from low-grade (slow-growing) to high-grade (fast-growing and more malignant) forms. Glioma is the most common form of central nervous system (CNS) neoplasm that originates from glial cells. Gliomas are very diffusely infiltrative tumors that affect the surrounding brain tissue. Glioblastoma is the most malignant type while pilocytic astrocytomas are the least malignant brain tumors. In the past, these diffuse gliomas were classified into different subtypes and grades based on histopathologies such as a diffuse astrocytoma, oligodendrogliomas, or mixed gliomas/oligoastrocytomas. Recently, gliomas were classified based on molecular and genetic markers. These advances have more specific prognostic and therapeutic benefits for patients with gliomas. In addition to molecular and genetic markers, gliomas are classified in grade I to IV based on the degree of proliferation indicated by the mitotic index and the presence or absence of necrosis. Gliomas are tumors derived from glial cells in the brain and nervous system. There are three major types of gliomas: astrocytomas (originating from astrocytes), oligodendrogliomas (from oligodendrocytes), and ependymomas (from ependymal cells). Gliomas are further classified into low-grade (I and II) and high-grade (III and IV) tumors based on cell morphology, mitotic activities, and molecular markers. The World Health Organization (WHO) grading system employs molecular markers to distinguish gliomas with significant prognostic and therapeutic implications. Astrocytomas can be either encapsulated or infiltrative, while oligodendrogliomas are less infiltrating than astrocytomas. Ependymomas are common in pediatric populations. High-grade gliomas, including glioblastomas, are the most aggressive forms of glioma and are life-threatening.

Headaches are the most common initial presenting symptom of patients with glioma. The pathophysiology of headaches is theorized to be the result of tumor growth that places a mass effect on surrounding tissue. The mass effect, in turn, leads to pressure in the microvasculature and leads to edema. Depending on the location of the tumor in the brain, the mass effect leads to signs of a brain tumor. For example, frontal lobe tumors can present with behavioral changes while dominant temporal lobe tumors can present with receptive speech problems. Other symptoms related to mass effects include nausea, vomiting, and change in vision, Seizures are the second most common symptom of presentation. The pathophysiology of seizures is attributed to tumor irritation to the cerebral cortex that leads to focal or generalized seizures. Other presenting symptoms of gliomas are tingling sensations, weakness, difficulty ambulation, and in rare cases, patients can present in a comatose state due to hemorrhage within the tumor which leads to an acute herniation syndrome.

Glioma treatment typically involves a multidisciplinary approach that includes surgery, radiation therapy, and chemotherapy Surgery is usually the first treatment option and involves removing as much of the tumor as possible. Radiation therapy and chemotherapy may be used after surgery to kill remaining tumor cells. In some cases, targeted therapy or immunotherapy may also be used. The specific treatment plan depends on the type, size, and location of the glioma, as well as the patient's health and preferences. If the glioma cannot be completely removed, treatments may focus on controlling symptoms and improving quality of life. Rehabilitation and supportive care, such as physical therapy and occupational therapy, may also be necessary to help patients regain lost motor skills or muscle strength. Complementary treatments, such as acupuncture, hypnosis, and music therapy, may also be helpful in managing symptoms.

“Glioma - Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Glioma pipeline landscape is provided which includes the disease overview and Glioma treatment guidelines. The assessment part of the report embraces, in depth Glioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Glioma R&D. The therapies under development are focused on novel approaches to treat/improve Glioma.

Glioma Emerging Drugs Chapters

This segment of the Glioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glioma Emerging Drugs

• AV-GBM-1: Aivita Biomedical, Inc.

AV-GBM-1 is an innovative immunotherapy developed by AIVITA Biomedical, Inc., specifically targeting glioblastoma (GBM), one of the most aggressive forms of brain cancer. This treatment utilizes autologous dendritic cells that are loaded with autologous tumor neoantigens derived from tumor-initiating cells. The therapy is administered through a series of subcutaneous injections and aims to enhance the immune response against the patient's unique cancer profile. Currently, the drug is in phase III stage of its clinical trial for the treatment of Glioma.

• DB 107: Denovo BioPharma

Denovo BioPharma's DB107 is an investigational gene therapy designed to treat high-grade gliomas, including glioblastoma (GBM), a particularly aggressive form of brain cancer. The therapy utilizes a novel biomarker-guided approach, leveraging the Denovo Genomic Marker 7 (DGM7) to identify patients who are likely to benefit from the treatment. Currently, the drug is in phase II stage of its clinical trial for the treatment of Glioma.

• MDNA55: Medicenna Therapeutics, Inc.

MDNA55 is a therapeutic for recurrent glioblastoma multiforme (rGBM), a uniformly fatal form of brain cancer. By using a highly specific IL-4 Superkine as the vehicle to deliver a potent bacterial toxin to the tumor cells, MDNA55 has the potential to purge bulk tumors and disrupt their supporting networks, while reactivating the immune system to tackle cancer. MDNA55 is designed to be a molecular trojan horse. It is a genetic fusion of two molecules: a circularly permuted IL-4 Superkine and the catalytic domain of the pseudomonas exotoxin A. Genetic fusion allows MDNA55 to harness the selectivity of the Superkine for cancers that overexpress the target IL-4 receptor (IL-4R) and deliver the cell-killing toxin directly into the tumor, its microenvironment and cancer stem cells. Since the IL-4 receptor is not found in a healthy brain and the exotoxin is only active in the cancer cell cytoplasm, this helps ensure that healthy cells are unaffected. When MDNA55 binds the target IL-4R, it is swallowed inside the tumor cell through a process called endocytosis. Once inside the tumor, proteases cleave the drug and activate the catalytic domain of the exotoxin to begin the process of apoptosis (cell death) involving a protein called elongation factor-2. Currently, the drug is in phase II stage of its clinical trial for the treatment of Glioma.

• Abemaciclib: Eli Lilly and Company

Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with Fulvestrant. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.

Abemaciclib selectively inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells. It is currently being evaluated in Phase II stage of development to treat patients with Glioblastoma.

• NMS-03305293: Nerviano Medical Sciences

NMS-293 is a second generation PARP inhibitor that differentiates from other approved or advanced molecules in its unique selectivity for PARP1 vs. PARP2 enzymes and low DNA trapping activity, both features potentially linked to lower hematological toxicity and higher potential for combination with DNA damaging agents in a wide range of tumors, covering high unmet medical needs. It also has a superior ability to penetrate the blood-brain barrier, a very important feature supporting its utilization in CNS tumors and brain metastases. The drug has shown high anti-tumor activity as single agent in BRCA mutated preclinical tumor models and synergy and tolerability in combination with chemotherapy. Based on the findings, NMS-293 is currently in clinical developmental Phase II in combination with temozolomide in recurrent glioblastoma.

• CAN-3110: Candel Therapeutics

CAN-3110 is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate designed with dual activity for oncolysis and immune activation in a single therapeutic. Its activity is designed to be conditional to the expression of Nestin in cancer cells. CAN-3110 is being evaluated in a phase I investigator-sponsored clinical trial in patients with recurrent HGG. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Glioma.

• MB-101: Mustang Bio

MB-101 is an IL13Rα2-targeted CAR T cell therapy developed by Mustang Bio, aimed at treating recurrent glioblastoma (GBM) and high-grade gliomas. Currently, the drug is in Phase I stage of clinical trial for the treatment of Glioma.

Glioma: Therapeutic Assessment

This segment of the report provides insights about the different Glioma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Glioma

There are approx. 180+ key companies which are developing the therapies for Glioma. The companies which have their Glioma drug candidates in the most advanced stage, i.e. Phase III include Aivita Biomedical, Inc.

Phases

The report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Glioma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Glioma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glioma drugs.

Glioma Report Insights

• Glioma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Glioma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Glioma drugs?
• How many Glioma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glioma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Glioma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Glioma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• CellabMED
• Oblato
• BioMed Valley Discoveries
• PharmAbcine
• I-Mab Biopharma
• Chimerix
• Medicenna Therapeutics
• Daiichi Sankyo
• Eli Lilly and Company
• Candel Therapeutics
• AstraZeneca
• Aveta Biomics
• Angiochem
• Arog Pharmaceuticals
• Boehringer Ingelheim
• BioMimetix
• Bexion Pharmaceuticals
• CANbridge Life Sciences
• Crimson Biopharma
• Epitopoietic Research Corporation
• Stemgen

Key Products

• YYB-103
• OKN-007
• Ulixertinib
• TTAC-0001
• TJ107
• ONC201
• MDNA55
• DS-1001b
• Abemaciclib
• CAN-2409
• AZD 1390
• Amax 126
• ANG1005
• Crenolanib
• BI 764532
• BMX-001
• BXQ-350
• CAN008
• CM93
• ERC1671
• hrBMP4

This product will be delivered within 3-5 business days.